Daiichi Sankyo Co., Ltd.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 2005-09-28

Employees: 18.7K

Market Cap: -

Website: http://www.daiichisankyo.co.jp

Clinical Trials

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Phase 2

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: DS-5141b

First Posted Date: 2020-06-16

Last Posted Date: 2024-08-29

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT04433234

Locations: 🇯🇵
National Center of Neurology and Psychiatry, Tokyo, Kodaira-Shi, Japan
🇯🇵
Kobe University Hospital, Hyōgo, Japan

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Advanced Cancer
Metastatic Solid Tumor

Interventions: Drug: DS-1055a

First Posted Date: 2020-06-05

Last Posted Date: 2024-11-12

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT04419532

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan

and more 3 locations

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Phase 1

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: DS-2741a
Drug: Placebo

First Posted Date: 2019-12-26

Last Posted Date: 2021-06-22

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT04211415

Locations: 🇯🇵
Osaka Pharmacology Clinical Research Hospital, Osaka, Japan

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Phase 2

Active, not recruiting

Conditions: Adult T-cell Leukemia/Lymphoma

Interventions: Drug: Valemetostat Tosylate

First Posted Date: 2019-09-25

Last Posted Date: 2024-02-16

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT04102150

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya-shi, Aichi, Japan
🇯🇵
Local Incorporated Administrative Agency Sasebo City General Hospital, Sasebo-shi, Nagasaki, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

and more 21 locations

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Phase 3

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Placebo
Drug: Mirogabalin

First Posted Date: 2019-09-19

Last Posted Date: 2022-10-24

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 393

Registration Number: NCT04094662

Locations: 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
🇨🇳
Cangzhou Central Hospital, Cangzhou, China
🇨🇳
Affiliated Zhongshan Hospital of Dalian University, Dalian, China

and more 37 locations

Study of Mirogabalin for Central Neuropathic Pain

Phase 3

Completed

Conditions: Central Neuropathic Pain

Interventions: Drug: Placebo
Drug: Mirogabalin

First Posted Date: 2019-04-03

Last Posted Date: 2024-10-21

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 300

Registration Number: NCT03901352

Locations: 🇯🇵
Hyogo Social Welfare Corporation Hyogo Rehabilitation Center Central Hospital, Hyōgo, Japan
🇯🇵
Funabashi Municipal Medical Center, Chiba, Japan
🇯🇵
Steel Memorial Yawata Hospital, Fukuoka, Japan

and more 115 locations

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Quizartinib

First Posted Date: 2018-10-29

Last Posted Date: 2022-07-29

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT03723681

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Milademetan

First Posted Date: 2018-09-14

Last Posted Date: 2023-11-07

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT03671564

Locations: 🇯🇵
Kyusyu University Hospital, Fukuoka, Japan
🇯🇵
Tenri Hospital, Nara, Japan
🇯🇵
Gifu Municipal Hospital, Gifu, Japan

and more 5 locations

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: DS-1205c
Drug: Gefitinib

First Posted Date: 2018-07-26

Last Posted Date: 2023-02-08

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT03599518

Locations: 🇯🇵
Aichi Cancer Center, Chikusa, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kindai University Hospital, Sayama, Osaka, Japan

and more 5 locations

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Phase 1

Active, not recruiting

Conditions: Hormone Receptor Positive Breast Cancer
Non-small Cell Lung Cancer
Triple Negative Breast Cancer

Interventions: Drug: Datopotamab Deruxtecan (Dato-DXd)
Drug: Steroid Containing Mouthwash
Other: Non-Steroid Containing Mouthwash

First Posted Date: 2018-01-17

Last Posted Date: 2024-12-03

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 890

Registration Number: NCT03401385

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy